Julie M. Vose
Nebraska Medical Center, Omaha, NE, USA · University of Nebraska
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Julie M. Vose as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:36 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02553447 · Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D DeficiencyUniversity of Nebraska · completed · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Untreated Chronic Lymphocytic Leukemia
- Ph2NCT01431209 · Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantUniversity of Nebraska · completed · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Ph2NCT01336933 · Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaUniversity of Nebraska · completed · Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Ph1NCT01336920 · Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaUniversity of Nebraska · completed · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- N/ANCT01142674 · T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell LymphomaAssociazione Angela Serra per la ricerca sul cancro · completed · Lymphoma, T-Cell, Peripheral · study chair
- Ph1/Ph2NCT01060384 · Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Non-Hodgkin's Lymphoma
- Early Ph1NCT00736450 · Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaUniversity of Nebraska · terminated · Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma
- N/ANCT00574626 · Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph1NCT00574509 · Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph1/Ph2NCT00571493 · VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell LymphomaUniversity of Nebraska · completed · Non-hodgkin's Lymphoma, Mantle Cell Lymphoma
- Ph1/Ph2NCT00572013 · Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph1NCT00243087 · Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)Boehringer Ingelheim · completed · Lymphoma · study chair
- Ph2NCT00004197 · Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph2NCT00004192 · Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma, Neutropenia
- Ph3NCT00004112 · Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph2NCT00004198 · Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma · study chair
- Ph2NCT00007852 · Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph3NCT00004874 · Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaUniversity of Nebraska · terminated · Lymphoma · study chair
- Ph2NCT00069966 · Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseTheradex · unknown · Lymphoma · study chair
- Ph1/Ph2NCT00031642 · Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell TransplantationUniversity of Nebraska · completed · Lymphoma
- Ph2NCT00007865 · Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma
- Ph2NCT00006478 · Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's LymphomaUniversity of Nebraska · terminated · Lymphoma
- Ph2NCT00006695 · Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's LymphomaUniversity of Nebraska · completed · Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Nebraska/Kansas Blood and Marrow Transplant Research NetworkU10HL069233 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 2011 to 2016 · $154,372 awarded in 2016Same name and institution; not confirmed by an ID
- Nebraska Blood and Marrow Transplant Research NetworkU01HL069233 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 2001 to 2010 · $150,504 awarded in 2010Same name and institution; not confirmed by an ID
- CORE--TISSUE PROCUREMENTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 1996 to 1999 · $100,486 awarded in 1999Grant number is on one of their registry trials
- TRANSPLANTATION FOR NHL--COMPARISON OF PSCT AND ABMTR01CA061488 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · fiscal years 1993 to 1996 · $165,830 awarded in 1996Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Epigenetic-based therapy of Hodgkin lymphomaP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANAS YOUNES · fiscal years 2009 to 2011Named on NCT01336920
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:36 UTC. The ranking covers the 200 most relevant of 81 PubMed records, and a shared surname and initials can bring in a namesake. All 81 on PubMed
- 988 citationsRCR 28.2
- 620 citationsRCR 13.2
- Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.N Engl J Med · 1991493 citationsRCR 14.9
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.J Clin Oncol · 2001455 citationsRCR 9.8
- Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.J Clin Oncol · 2001335 citationsRCR 6.9
- Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.J Clin Oncol · 2008334 citationsRCR 6.9
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Ann Oncol · 2011329 citationsRCR 7.9
- Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.J Clin Oncol · 2000268 citationsRCR 6.1
- 260 citationsRCR 8.2
- Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.J Clin Oncol · 2011256 citationsRCR 6.0